MBTPS1 and multiple sclerosis: Also, lipids including HDL play an important role as S1P chaperones; therefore, alterations in lipoprotein metabolism could influence the efficacy of drugs modulating the S1P pathway (e.g., fingolimod), which are now used in multiple sclerosis and being investigated in AIRDs (34, 179).